Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

SRZN vs VIVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–0 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: SRZN 3 – 2 VIVS (1 Tie) Matrix Metrics: SRZN 7 – 0 VIVS

As of Nov 19, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SRZN carries a Unified Composite Score of 42.8/100 (HOLD) at $30.67 (N/M Forward P/E, -485.4% operating margin), whereas VIVS carries 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin).

  • Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.8); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs VIVS
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$30.67
-3.37% 1D
Market Cap $665.1M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.25β · 70% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.6% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $30.32 · SMA50: $26.74
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18

6-Pillar Scorecard Institutional Category Breakdown (SRZN 3 – 2 VIVS)

Columns: Metric · SRZN · VIVS
1. Valuation Multiples VIVS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 54.2x 9.6x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% -51.4%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $112,000
Market Cap $665.1M $2.4M
3. Profitability & Quality SRZN
Gross Margin N/A N/A
Operating Margin -485.4% -10117.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -343.1%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$31M -$11M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $1.4M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 72.0% (5th %ile) N/A (N/A)
Put/Call OI Skew 2.00x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (7) vs VIVS (0)
Institutional Metric SRZN VIVS Criterion Row Edge
Market Capitalization
Scale
$665.1M $2.4M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% -51.4% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% -10117.0% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -343.1% Higher ROE SRZN
52-Week Range Position
Momentum
72% ($13–$38) 5% ($0–$3) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.25β · 70% Vol 0.83β · 480% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
42.8 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite SRZN
Trailing 12M Revenue (USD)
Operating Scale
$11M $112,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 54.2x EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$11M EBITDA ($1.4M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +43.56 pp
SRZN: +21.13% · VIVS: +64.69%
3M Horizon SRZN +25.92 pp
SRZN: +27.84% · VIVS: +1.92%
6M Horizon SRZN +91.47 pp
SRZN: +13.22% · VIVS: -78.25%
1Y Horizon SRZN +223.82 pp
SRZN: +136.83% · VIVS: -86.99%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue VIVS Revenue SRZN Op. Margin VIVS Op. Margin Margin Leader
FY2018 N/A $0M N/A -766.3% VIVS
FY2019 N/A $0M N/A -882.4% VIVS
FY2020 N/A $0M N/A -977.9% VIVS
FY2022 $10M $0M -354.7% -765.3% SRZN
FY2023 N/A $0M N/A -4792.2% VIVS
FY2024 $10M $0M -239.7% -13840.4% SRZN
FY2025 $0M $0M -1210.6% -8761.1% SRZN
FY2026 N/A $0M N/A -8768.7% VIVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
40d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew 2.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $665.1M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs VIVS Key Questions & Quantitative Answers

As of Nov 19, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SRZN carries a Unified Composite Score of 42.8/100 (HOLD) at $30.67 (N/M Forward P/E, -485.4% operating margin), whereas VIVS carries 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin). Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.8); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with VIVS at -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), SRZN cumulative revenue shifted +0.0% while VIVS shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VIVS.

VIVS screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 54.2x EV/Revenue (unreported FCF margin), whereas VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus VIVS (-343.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), a 2.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.25β · 70% Vol realized risk). By comparison, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.